Big pharma companies are ramping up the number of female bosses in Japan, with the percentage of women in managerial posts reaching 20% or more for seven out of 10 firms that disclosed their most recent data to Jiho by…
REGULATORY
MHLW Panel OKs 5-Year Extension of Pneumovax Transitional Measure
A health ministry panel agreed on January 10 to extend for five years a transitional measure related to the vaccination of MSD’s 23-valent pneumococcal vaccine Pneumovax in the elderly under the publicly funded immunization program. Pneumovax was added to the…
To read the full story
Related Article
- MHLW Panel to Discuss Changing Current Transitional Period for Pneumococcal Vaccinations in Elderly
November 2, 2018
- MHLW Presents Schedule for Discussions on Inclusion of 6 Vaccines in Public Vaccination Programs
May 21, 2018
- MHLW to Start Discussions on Pneumovax Vaccination in Post-Transition Period
September 15, 2017
REGULATORY
- PMDA to Prohibit Staffers from Trading Pharma Shares
June 17, 2019
- PMDA to Discuss Optimal Use of Xofluza amid Concerns over Resistant Viruses
June 17, 2019
- 10 More Hospitals to Join MID-NET Database, Covering Data on 6 Million Patients
June 17, 2019
- PMDA Reviewing Risks for Ibrance, Opdivo, Keytruda and More
June 17, 2019
- LDP’s Pharma Study Group Submits Proposal to Health Minister, Calls for PMP Revamp in 2020 Reform
June 13, 2019
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…